



April 10, 2017

FIELD ACTION NOTIFICATION

Synchron Systems Cholesterol, Creatinine, HDL Cholesterol, Lactate, Triglyceride, Uric Acid and Salicylate Reagents

REF	LOT	
467825 (CHOL)	All Lots	NA
A60298 (CR-E)		
A15625 (HDL)		
A95550 (LACT)		
445850 (TG and TG-B)		
442785 (URIC)		
378194 (SALY)		

Attention Beckman Coulter Customer,
Copy: Chairman Medical Board/Head of Departments of Affected consignees

Beckman Coulter is initiating a field action for the product listed above. This letter contains important information that needs your immediate attention.

ISSUE:	<ul style="list-style-type: none">Beckman Coulter has identified the following drugs as potential sources of interference:<ul style="list-style-type: none">Metamizole (Dipyrone) – Analgesic/antispasmodic/antipyretic Note: No longer approved for sale in certain geographies, including the US and Canada.Sulfasalazine – Anti-inflammatorySulfapyridine – Sulfonamide antibiotic
IMPACT:	<ul style="list-style-type: none">With the administration of these drugs, the effects to patient analytes are:

	<ul style="list-style-type: none"> ○ Metamizole (Dipyrone) – may generate false low Cholesterol, Enzymatic Creatinine, HDL Cholesterol, Lactate, Triglycerides and Uric Acid results. ○ Sulfasalazine – may generate false high Salicylate results. ○ Sulfapyridine – may generate false low Salicylate results.
ACTION:	No action is required by your laboratory. No retrospective review of results is recommended.
RESOLUTION:	<ul style="list-style-type: none"> • The following statement will be added to the respective INTERFERENCES sections of the CHOL, CR-E, HDL, LACT, TG, TG-B and URIC* Chemistry Information Sheets (CIS): <p style="margin-left: 40px;"><i>Venipuncture immediately after or during the administration of Metamizole (Dipyrone) may lead to false low results for [analyte name*]. Venipuncture should be performed prior to the administration of Metamizole.</i></p> • The following statements will be added to the INTERFERENCES section of the SALY Chemistry Information Sheets (CIS): <p style="margin-left: 40px;"><i>Patients treated with Sulfasalazine may generate a false high result for Salicylate.</i></p> <p style="margin-left: 40px;"><i>Patients treated with Sulfapyridine may generate a false low result for Salicylate.</i></p> <p>This communication serves as temporary labeling until the Chemistry Information Sheets (CIS) are updated. CIS are available on the Beckman Coulter website’s “Technical Documents” webpage: https://www.beckmancoulter.com/wsrportal/page/techdocSearch</p>

Please share this information with your laboratory staff and retain this notification as part of your laboratory Quality System documentation. If you have forwarded any of the affected product(s) listed above to another laboratory, please provide them a copy of this letter.


Please complete and return the enclosed Response Form within 10 days so we are assured you have received this important communication.

If you have any questions regarding this notice, please contact our Customer Support Center

- Via our website, <http://www.beckmancoulter.com/customersupport/support>
- Via phone, call 1-800-854-3633 in the United States and Canada
- Outside the United States and Canada, contact your local Beckman Coulter Representative.

We apologize for any inconvenience that this caused your laboratory.

Sincerely,



David Davis
Director, Regulatory Affairs

Enclosure:
Response Form

Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc., in the United States and other countries.

FA-29156
Beckman Coulter, Inc.
250 S. Kraemer Boulevard
Brea, CA 92821

Mailing Address:
250 S. Kraemer Boulevard
P.O. Box 8000
Brea, CA 92822-8000

Telephone: (800) 526-3821
Facsimile: (714) 961-4234
Internet: www.beckmancoulter.com